# DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

> **NCT02744053** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 96 (actual)

## Conditions studied

- Estrogen Receptor Negative
- HER2/Neu Negative
- Progesterone Receptor Negative
- Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Scintimammography
- **DRUG:** Technetium Tc-99m Sestamibi

## Key facts

- **NCT ID:** NCT02744053
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-07
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02744053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02744053, "DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02744053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*